Jade Biosciences announced that new preclinical data on JADE101, its investigational anti-APRIL monoclonal antibody for IgA nephropathy (IgAN), will be presented at the 62nd European Renal Association (ERA) Congress in Vienna from June 4-7, 2025. The biotechnology company, focused on developing therapies for autoimmune diseases, will showcase findings from its lead therapeutic candidate during a focused oral session.
Presentation Details and Clinical Development Timeline
The presentation, titled "Discovery and Characterization of JADE101, an Ultra-High Affinity, Half-Life Extended Anti-APRIL Monoclonal Antibody for the Treatment of IgAN," will be delivered by Erin Filbert, Executive Director and Head of Research and Translational Medicine at Jade Biosciences. The session is scheduled for Friday, June 6, 2025, at 4:30 p.m. CET during the Focused Oral Session on Glomerular and Tubulo-Interstitial Diseases.
Jade Biosciences expects to initiate a first-in-human clinical trial for JADE101 in the second half of 2025, marking a significant milestone in the development of this novel therapeutic approach for IgA nephropathy.
JADE101 Mechanism and Design Features
JADE101 is an investigational anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody specifically developed for treating IgA nephropathy, a chronic autoimmune kidney disease. The condition is characterized by the deposition of pathogenic IgA-containing immune complexes in the kidneys, which can lead to proteinuria, declining kidney function, and potentially end-stage kidney disease requiring dialysis or transplantation.
By targeting APRIL, a protein involved in the overproduction of IgA, JADE101 aims to reduce the levels of disease-driving IgA, decrease proteinuria, and preserve kidney function. The antibody has been engineered with half-life extension technology, designed for dosing at intervals of at least eight weeks, offering the potential for durable clinical activity and improved patient convenience.
Addressing Unmet Medical Needs
The extended dosing interval is particularly important for IgA nephropathy, a condition often diagnosed in young adulthood and potentially requiring life-long treatment. This design feature could significantly improve treatment adherence and quality of life for patients managing this chronic autoimmune kidney disease.
Company Pipeline and Background
Jade Biosciences' pipeline includes JADE101 as its lead candidate, along with a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. The company was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.
The company will host a conference call and webcast on Monday, June 9, 2025, at 8:00 a.m. ET to discuss the new JADE101 data presented at the ERA Congress, providing investors and the public with detailed insights into the preclinical findings and their implications for the therapeutic development program.
